Article
Medicine, General & Internal
Haruna Furukawa, Jun Nomura, Masahiro Kobayashi, Shori Abe, Tomoki Takeda, Yumiko Oka, Yuko Shirota, Takao Kodera, Yoko Okitsu, Shinichiro Takahashi, Keigo Murakami, Junichi Kameoka
Summary: A 78-year-old man with myelodysplastic syndromes was treated with lenalidomide, but developed immune thrombocytopenic purpura resistant to platelet transfusions, resulting in severe thrombocytopenia and death from gastrointestinal hemorrhage.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Review
Oncology
Isaac Park, Tra Mi Phan, Jing Fang
Summary: Lenalidomide and other IMiDs have shown clinical efficacy in certain subtypes of hematologic malignancies, such as multiple myeloma and lower-risk MDS with del(5q). Despite superior clinical response, relapse and resistance are still challenges in IMiD therapy. Recent studies have revealed novel molecular mechanisms of IMiD-based anti-tumor therapy.
Article
Hematology
Anna Hecht, Julia A. Meyer, Johann-Christoph Jann, Katja Sockel, Aristoteles Giagounidis, Katharina S. Goetze, Anne Letsch, Detlef Haase, Richard F. Schlenk, Torsten Haferlach, Philippe Schafhausen, Gesine Bug, Michael Luebbert, Felicitas Thol, Guntram Buesche, Esther Schuler, Verena Nowak, Julia Oblaender, Stephanie Fey, Nadine Mueller, Georgia Metzgeroth, Wolf-Karsten Hofmann, Ulrich Germing, Florian Nolte, Mark Reinwald, Daniel Nowak
Summary: This study aimed to investigate whether global DNA methylation patterns could predict response to lenalidomide in patients with myelodysplastic syndrome (MDS) with isolated deletion of chromosome 5q (MDS del5q). Results showed no significant effect of lenalidomide on DNA methylation status, and methylation patterns before treatment were not predictive of lenalidomide response. Some patients with hypermethylation of DNA sequences showed a trend towards inferior overall survival, suggesting the need to evaluate novel therapeutic targets.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Alan F. List, Zhuoxin Sun, Amit Verma, John M. Bennett, Rami S. Komrokji, Kathy McGraw, Jaroslaw Maciejewski, Jessica K. Altman, Puneet S. Cheema, David F. Claxton, Selina M. Luger, Ryan J. Mattison, Timothy R. Wassenaar, Andrew S. Artz, Charles A. Schiffer, Mark R. Litzow, Martin S. Tallman
Summary: The combination of lenalidomide and epoetin alfa significantly improves major erythroid response in lower-risk, non-del(5q) MDS patients compared to lenalidomide alone, with a higher rate and longer duration of response.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Hematology
Sangeetha Venugopal, John Mascarenhas, David P. Steensma
Summary: Hemizygous interstitial or terminal deletion of chromosome 5q is a recurrent cytogenetic abnormality in myeloid malignancies, with differing clinical implications in MDS and AML. Lenalidomide effectively targets the del(5q)-bearing clone, leading to erythroid transfusion independence and cytogenetic remission in some patients, but novel targeted therapeutic strategies are still needed for lenalidomide-refractory cases.
Article
Medicine, General & Internal
Nyomi R. Washington, Eugen A. Shippey, Michael Osswald
Summary: Lenalidomide is effective in treating both multiple myeloma and myelodysplastic syndrome with isolated del(5q), as shown in a case report where a patient with both conditions achieved a complete response with lenalidomide, bortezomib, and dexamethasone treatment within three months. This suggests that standard induction regimens containing lenalidomide and a proteasome inhibitor may be safe and effective for patients with concurrent diagnoses of multiple myeloma and MDS with isolated del(5q).
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Oncology
Kazumasa Aoyama, Daisuke Shinoda, Emi Suzuki, Yaeko Nakajima-Takagi, Motohiko Oshima, Shuhei Koide, Ola Rizq, Sha Si, Shiro Tara, Goro Sashida, Atsushi Iwama
Summary: Deletion of Ezh1 and Ezh2 leads to PRC2 insufficiency, causing dyserythropoiesis and activating the p53 pathway by de-repressing the Cdkn2a gene, contributing to disease progression. Rescuing dyserythropoiesis can be achieved by deleting Cdkn2a and p53.
Article
Medicine, General & Internal
Hai-Ping Liang, Xing-Chun Luo, Ya-Li Zhang, Bei Liu
Summary: This study reported a case of MDS with both del(5q) and inv(3), which is associated with a poor prognosis. Azacitidine may achieve short-term remission for such patients.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Article
Medicine, General & Internal
Sherif Elkattawy, Sarah Ayad, Iman El-Feki, Xutong Guo, Edmund Appiah-Kubi, Afrah Talpur, William Kessler
Summary: Myelodysplastic syndromes are a diverse group of hematopoietic stem cell malignancies characterized by abnormal differentiation of bone marrow cell lines, with a large part of the phenotypic variability attributed to a wide set of genetic defects. Among these, 5q syndrome, identified by an isolated deletion of the long arm of chromosome 5, is the only subset to be diagnosed by genetic defects. Diagnosis usually involves bone marrow biopsy and FISH panel testing, with common clinical features including anemia, thrombocytopenia, and dysplastic bone marrow.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Oncology
Anna Stein, Anne Sophie Kubasch, Claudia Haferlach, Uwe Platzbecker
Summary: This study presents three personalized therapy cases of MDS with del(5q), with lenalidomide as the treatment option, including a rare case with a unique response.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Junshik Hong, Yoo Jin Lee, Sung Hwa Bae, Jun Ho Yi, Sungwoo Park, Myung Hee Chang, Young Hoon Park, Shin Young Hyun, Joo-Seop Chung, Ji Eun Jang, Joo Young Jung, So-Yeon Jeon, Seo-Young Song, Hawk Kim, Dae Sik Kim, Sung-Hyun Kim, Min Kyoung Kim, Sang Hoon Han, Seonyang Park, Yoo-Jin Kim, Je-Hwan Lee
Summary: In a nationwide retrospective analysis in Korea, lenalidomide was effective and tolerable for del(5q) MDS patients with transfusion-dependent anemia, with RBC transfusion independence achieved in 67.9% of evaluable patients. Female sex and thrombocytopenia were associated with better outcomes. The most common non-hematologic toxicities were pruritus, fatigue, and rashes, with dose reduction required for most responders.
Article
Hematology
Shuji Uno, Yoko Motegi, Kenichi Minehata, Yasuo Aoki
Summary: Lenalidomide was approved in Japan for the treatment of patients with del 5q-MDS. A post-marketing surveillance study found that 78.0% of patients experienced adverse drug reactions (ADRs), with thrombocytopenia or platelet count decreased being the most common ADR. 11.0% of patients had confirmed acute myeloid leukemia (AML) progression during the study.
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Faezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, Pamela Lockyer, Guillermo Montalban-Bravo, Marcos Estecio, Yue Lu, Kelly A. Soltysiak, Kelly S. Chien, Hui Yang, Koji Sasaki, Caleb Class, Irene Ganan-Gomez, Kim-Anh Do, Guillermo Garcia-Manero, Yue Wei
Summary: Research in CMML and MDS patients found that treatment failure with HMAs may be associated with changes in immunoglobulin genes and GABA receptor signaling, providing potential biological markers and therapeutic targets for further study.
EXPERIMENTAL HEMATOLOGY
(2022)
Review
Oncology
Pamela Acha, Mar Mallo, Francesc Sole
Summary: Myelodysplastic syndromes with isolated del(5q) are a subtype of MDS defined by cytogenetic alteration. This review summarizes the current knowledge of the molecular background of MDS with isolated del(5q), focusing on the clinical and prognostic relevance of cytogenetic alterations and somatic mutations.
Article
Oncology
Yanqing Zhang, Yang Liu, Tong Wang, Hui Wang, Xue Chen, Panxiang Cao, Xiaoli Ma, Mingyue Liu, Ping Xu, Hailiang Bi, Jiaqi Pan, Yongfang Jiang, Xiaoyun Li, Wei Wang, Hongxing Liu
Summary: This study reports the identification of BCR:ABL1 and MSI2:PC fusion genes in MDS patients, with dynamic changes observed during disease progression. Furthermore, mutations in driver genes were also identified. These findings contribute to a better understanding of the molecular significance of BCR:ABL1, MSI2, and PC.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Q. Zhang, M. C. Ball, Y. Zhao, M. Balasis, C. Letson, A. Vedder, A. F. List, P. K. Epling-Burnette, R. S. Komrokji, E. Padron
Article
Oncology
Y. Mei, B. Zhao, A. A. Basiorka, J. Yang, L. Cao, J. Zhang, A. List, P. Ji
Article
Cell Biology
Era L. Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, John E. Godwin, Min Fang, Kenneth J. Kopecky, Alan F. List, Galina L. Pogosov, Jerald P. Radich, Cheryl L. Willman, Brent L. Wood, Soheil Meshinchi, Derek L. Stirewalt
BIOPRESERVATION AND BIOBANKING
(2018)
Letter
Hematology
Kathy L. McGraw, Johnny Nguyen, Najla H. Al Ali, Rami S. Komrokji, David Sallman, Xiaohui Zhang, Jinming Song, Eric Padron, Jeffrey E. Lancet, Lynn C. Moscinski, Alan F. List, Ling Zhang
BRITISH JOURNAL OF HAEMATOLOGY
(2019)
Review
Oncology
Alan List, Benjamin L. Ebert, Pierre Fenaux
Article
Oncology
Sandrine Niyongere, Nolwenn Lucas, Jun-Min Zhou, Samer Sansil, Anthony D. Pomicter, Maria E. Balasis, John Robinson, Jodi Kroeger, Qing Zhang, Yu Long Zhao, Markus Ball, Rami Komrokji, Alan List, Michael W. Deininger, Brooke L. Fridley, Valeria Santini, Eric Solary, Eric Padron
Article
Oncology
Anjali S. Advani, Hongli Li, Laura C. Michaelis, Bruno C. Medeiros, Michaela Liedtke, Alan F. List, Kristen O'Dwyer, Megan Othus, Harry P. Erba, Frederick R. Appelbaum
Article
Hematology
Andrew T. Kuykendall, Chetasi Talati, Eric Padron, Kendra Sweet, David Sallman, Alan F. List, Jeffrey E. Lancet, Rami S. Komrokji
AMERICAN JOURNAL OF HEMATOLOGY
(2019)
Article
Oncology
Rami S. Komrokji, Sheng Wei, Adam W. Mailloux, Ling Zhang, Eric Padron, David Sallman, Jeffrey E. Lancet, Sara Tinsley, Lisa A. Nardelli, Javier Pinilla-Ibarz, Pearlie K. Epling-Burnette, Alan F. List
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2019)
Review
Hematology
Jung-hoon Lee, Alan List, David A. Sallman
EUROPEAN JOURNAL OF HAEMATOLOGY
(2019)
Article
Oncology
Detlef Haase, Kristen E. Stevenson, Donna Neuberg, Jaroslaw P. Maciejewski, Aziz Nazha, Mikkael A. Sekeres, Benjamin L. Ebert, Guillermo Garcia-Manero, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern, Seishi Ogawa, Yasunobu Nagata, Kenichi Yoshida, Timothy A. Graubert, Matthew J. Walter, Alan F. List, Rami S. Komrokji, Eric Padron, David Sallman, Elli Papaemmanuil, Peter J. Campbell, Michael R. Savona, Adam Seegmiller, Lionel Ades, Pierre Fenaux, Lee-Yung Shih, David Bowen, Michael J. Groves, Sudhir Tauro, Michaela Fontenay, Olivier Kosmider, Michal Bar-Natan, David Steensma, Richard Stone, Michael Heuser, Felicitas Thol, Mario Cazzola, Luca Malcovati, Aly Karsan, Christina Ganster, Eva Hellstrom-Lindberg, Jacqueline Boultwood, Andrea Pellagatti, Valeria Santini, Lynn Quek, Paresh Vyas, Heinz Tuechler, Peter L. Greenberg, Rafael Bejar
Review
Hematology
David A. Sallman, Alan List
Article
Oncology
Pinyang Cheng, Erika A. Eksioglu, Xianghong Chen, Wendy Kandell, Thu Le Trinh, Ling Cen, Jin Qi, David A. Sallman, Yu Zhang, Nhan Tu, William A. Adams, Chunze Zhang, Jinhong Liu, John L. Cleveland, Alan F. List, Sheng Wei
Article
Hematology
Andrew T. Kuykendall, Savan Shah, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji
ANNALS OF HEMATOLOGY
(2018)
Article
Hematology
Vu H. Duong, Eric Padron, Najla H. Al Ali, Jeffrey E. Lancet, Jeff Hall, Brian Kwok, Ling Zhang, Pearlie K. Epling-Burnette, Alan F. List, Rami S. Komrokji
ANNALS OF HEMATOLOGY
(2018)